321853-33-2

Upstream product

• 1757-42-2 3-methyl-cyclopentanone 
• 67-66-3 chloroform 
• 321853-32-1 4-[[(3-chloro-5-methylanilino)carbonyl]methyl]phenol 
• 29027-20-1 3-chloro-5-methylaniline 
• 89-62-3 4-methyl-2-nitroaniline 
• 5465-33-8 2-chloro-4-methyl-6-nitroaniline 
• 16582-38-0 3-chloro-5-nitrotoluene 

Relevant academic research and scientific papers

Substituted chiral allosteric hemoglobin modifiers

A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

Synthesis and structure - Activity relationships of chiral allosteric modifiers of hemoglobin

A series of allosteric effectors of hemoglobin, 2-(aryloxy)-2-alkanoic acids, was prepared to investigate the effect of the stereocenter on allosteric activity. The chiral analogues were based on the lead compound, RSR13 (3b), with different alkyl/alkanoic and cycloalkyl/cycloalkanoic groups positioned at the acidic chiral center. Of the 23 racemic molecules synthesized, 5 were selected for resolution based on structure - activity relationships. One chiral analogue, (-)-(1R,2R)-1-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylcycl opentanecarboxylic acid (11), exhibited greater in vitro activity in hemoglobin solutions than its antipode, racemate, and RSR13. Compound (-)-(1R,2R)-11 was equipotent with RSR13 in whole blood, is a candidate for in vivo animal studies, and if efficacious and safe has a potential for use in humans. In general, it was found that chirality affects allosteric effector activity with measurable differences observed between enantiomers and the racemates.